Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology

The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics

Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864

Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy

Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359

Inflammation and Alzheimer’s disease

Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514

Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo

Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291

Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles

Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126

Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis

Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064

Hearing loss and cognitive decline in older adults

Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017

β-Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE

Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876

Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins

Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506

Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.

Griffin, W. S., Stanley, L. C., Ling, C., White, L., MacLeod, V, Perrot, L. J., White, C. L., & Araoz, C. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.19.7611 · Cited by 1,777

Down's syndrome

Roizen, N., & Patterson, D. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12987-x · Cited by 1,386

Alzheimer’s Disease Risk Genes and Mechanisms of Disease Pathogenesis

Karch, C. M., & Goate, A. M. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.05.006 · Cited by 1,357

APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy

Rovelet‐Lecrux, A., Hannequin, D., Raux, G., Meur, N. L., Laquerrière, A., Vital, A., Dumanchin‐Njock, C., Feuillette, S., Brice, A., Vercelletto, M., et al. (2005) · Nature Genetics · doi:10.1038/ng1718 · Cited by 1,284

Alzheimer disease: Epidemiology, diagnostic criteria, risk factors and biomarkers

Reitz, C., & Mayeux, R. P. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.024 · Cited by 1,271

Occurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome

Wisniewski, K. E., Wisniewski, H. M., & Wen, G. Y. (1985) · Annals of Neurology · doi:10.1002/ana.410170310 · Cited by 1,159

Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer's disease

Tanzi, R. E., McClatchey, A. I., Lamperti, E. D., Villa‐Komaroff, L., Gusella, J. F., & Neve, R. L. (1988) · Nature · doi:10.1038/331528a0 · Cited by 1,093

Cerebral amyloid angiopathy. A critical review.

Vinters, H. V. (1987) · Stroke · doi:10.1161/01.str.18.2.311 · Cited by 1,070

Alzheimer's disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss

Gong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E., Krafft, G. A., & Klein, W. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1834302100 · Cited by 1,061

The cholinergic system in aging and neuronal degeneration

Schliebs, R., & Arendt, T. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.11.058 · Cited by 1,047

Intraneuronal Aβ42 Accumulation in Human Brain

Gouras, G. K., Tsai, J., Naslund, J., Vincent, B., Edgar, M., Checler, F., Greenfield, J. P., Haroutunian, V., Buxbaum, J. D., Xu, H., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64700-1 · Cited by 991

Normal and Abnormal Biology of the Beta-Amyloid Precursor Protein

Selkoe, D. J. (1994) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.17.030194.002421 · Cited by 834

Untitled work

(1959) · PubMed · Cited by 820

Endocytic Pathway Abnormalities Precede Amyloid β Deposition in Sporadic Alzheimer’s Disease and Down Syndrome

Cataldo, A. M., Peterhoff, C. M., Troncoso, J. C., Gomez-Isla, T., Hyman, B. T., & Nixon, R. A. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64538-5 · Cited by 776

The Relationship between Aβ and Memory in the Tg2576 Mouse Model of Alzheimer's Disease

Westerman, M. A., Cooper-Blacketer, D., Mariash, A., Kotilinek, L., Kawarabayashi, T., Younkin, L. H., Carlson, G. A., Younkin, S. G., & Ashe, K. H. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01858.2002 · Cited by 731

Amyloid A4 Protein and Its Precursor in Down's Syndrome and Alzheimer's Disease

Rumble, B. A., Retallack, R. W., Hilbich, C., Simms, G., Multhaup, G., Martins, R. N., Hockey, A., Montgomery, P., Beyreuther, K. T., & Masters, C. L. (1989) · New England Journal of Medicine · doi:10.1056/nejm198906013202203 · Cited by 656

Mechanisms of tau-induced neurodegeneration

Iqbal, K., Liu, F., Gong, C.-X., Alonso, A. D. C., & Grundke-Iqbal, I. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0486-3 · Cited by 628

Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E

Barger, S. W., & Harmon, A. D. (1997) · Nature · doi:10.1038/42257 · Cited by 622

Water-soluble Aβ(N-40, N-42) oligomers in normal and Alzheimer disease brains

Kuo, Y.-M., Emmerling, M. R., Vigo-Pelfrey, C., Kasunic, T. C., Kirkpatrick, J. B., Murdoch, G. H., Ball, M. J., & Roher, A. E. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.8.4077 · Cited by 618

Vascular contributions to cognitive impairment and dementia including Alzheimer's disease

Snyder, H. M., Corriveau, R. A., Craft, S., Faber, J. E., Greenberg, S. M., Knopman, D., Lamb, B. T., Montine, T. J., Nedergaard, M., Schaffer, C. B., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.10.008 · Cited by 603

Dominant and differential deposition of distinct β-amyloid peptide species, AβN3(pE), in senile plaques

Saido, T. C., Iwatsubo, T., Mann, D. M. A., Shimada, H., Ihara, Y., & Kawashima, S. (1995) · Neuron · doi:10.1016/0896-6273(95)90301-1 · Cited by 587

Sequence of Deposition of Heterogeneous Amyloid β-Peptides and APO E in Down Syndrome: Implications for Initial Events in Amyloid Plaque Formation

Lemere, C. A., Blusztajn, J. K., Yamaguchi, H., Wisniewski, T., Saido, T. C., & Selkoe, D. J. (1996) · Neurobiology of Disease · doi:10.1006/nbdi.1996.0003 · Cited by 584

A Prospective Study of Alzheimer Disease in Down Syndrome

Lai, F., & Williams, R. S. (1989) · Archives of Neurology · doi:10.1001/archneur.1989.00520440031017 · Cited by 561

Clearing the brain's amyloid cobwebs

Selkoe, D. J. (2001) · Neuron · doi:10.1016/s0896-6273(01)00475-5 · Cited by 541

Disease‐specific patterns of locus coeruleus cell loss

German, D. C., Manaye, K. F., White, C. L., Woodward, D. J., McIntire, D. D., Smith, W. K., Kalaria, R. N., & Mann, D. M. A. (1992) · Annals of Neurology · doi:10.1002/ana.410320510 · Cited by 512

Regulation of APP cleavage by α‐, β‐ and γ‐secretases

Nunan, J., & Small, D. H. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)02076-7 · Cited by 509

Amyloid-β oligomers: their production, toxicity and therapeutic inhibition

Walsh, D. M., Klyubin, I. V., Fadeeva, J. V., Rowan, M. J., & Selkoe, D. J. (2002) · Biochemical Society Transactions · doi:10.1042/bst0300552 · Cited by 507

The four ages of Down syndrome.

Bittles, A., Bower, C., Hussain, R., & Glasson, E. (2007) · European Journal of Public Health · doi:10.1093/eurpub/ckl103 · Cited by 505

Cognitive deficits and associated neurological complications in individuals with Down's syndrome

Lott, I. T., & Dierssen, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70112-5 · Cited by 484

The changing survival profile of people with Down's syndrome: implications for genetic counselling

Glasson, E. J., Sullivan, S. G., Hussain, R., Petterson, B. A., Montgomery, P. D., & Bittles, A. H. (2002) · Clinical Genetics · doi:10.1034/j.1399-0004.2002.620506.x · Cited by 477

The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome

Mann, D. M. A., & Esiri, M. M. (1989) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(89)90019-1 · Cited by 471

Assessing Activation States in Microglia

Colton, C. A., & Wilcock, D. M. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710791012053 · Cited by 430

Altered Metabolism of the Amyloid β Precursor Protein Is Associated with Mitochondrial Dysfunction in Down's Syndrome

Busciglio, J., Pelsman, A., Wong, C., Pigino, G., Yuan, M., Mori, H., & Yankner, B. A. (2002) · Neuron · doi:10.1016/s0896-6273(02)00604-9 · Cited by 387

Amyloid β protein (Aβ) deposition: Aβ42(43) precedes Aβ40 in down Syndrome

Iwatsubo, T., Mann, D. M. A., Odaka, A., Suzuki, N., & Ihara, Y. (1995) · Annals of Neurology · doi:10.1002/ana.410370305 · Cited by 386

Aβ localization in abnormal endosomes: association with earliest Aβ elevations in AD and Down syndrome

Cataldo, A. M., Petanceska, S., Terio, N. B., Peterhoff, C. M., Durham, R., Mercken, M., Mehta, P. D., Buxbaum, J., Haroutunian, V., & Nixon, R. A. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.02.027 · Cited by 363

Pathology and pathogenesis of vascular cognitive impairment—a critical update

Jellinger, K. A. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00017 · Cited by 353

Intraneuronal Aβ accumulation precedes plaque formation in β-amyloid precursor protein and presenilin-1 double-transgenic mice

Wirths, O., Multhaup, G., Czech, C., Blanchard, V., Moussaoui, S., Tremp, G., Pradier, L., Beyreuther, K., & Bayer, T. A. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01876-6 · Cited by 336

Presence of soluble amyloid β–peptide precedes amyloid plaque formation in Down's syndrome

Teller, J. K., Russo, C., DeBusk, L. M., Angelini, G., Zaccheo, D., Dagna-Bricarelli, F., Scartezzini, P., Bertolini, S., Mann, D. M. A., Tabaton, M., et al. (1996) · Nature Medicine · doi:10.1038/nm0196-93 · Cited by 326

Neuronal Oxidative Stress Precedes Amyloid-β Deposition in Down Syndrome

Nunomura, A., Perry, G. L., Pappolla, M. A., Friedland, R. P., Hirai, K., Chiba, S., & Smith, M. A. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.11.1011 · Cited by 324

Age‐dependent cognitive decline in the APP23 model precedes amyloid deposition

Dam, D. V., D’Hooge, R., Staufenbiel, M., Ginneken, C. J. V., Meir, F. V., & Deyn, P. P. D. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02444.x · Cited by 300

Down syndrome and Alzheimer's disease: common pathways, common goals

Hartley, D., Blumenthal, T., Carrillo, M., DiPaolo, G., Esralew, L., Gardiner, K., Granholm, A.-C., Iqbal, K., Krams, M., Lemere, C., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.10.007 · Cited by 290

Profiles of neuropsychological impairment in autopsy-defined Alzheimer's disease and cerebrovascular disease

Reed, B. R., Mungas, D. M., Kramer, J. H., Ellis, W., Vinters, H. V., Zarow, C., Jagust, W. J., & Chui, H. C. (2007) · Brain · doi:10.1093/brain/awl385 · Cited by 282

The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between β-amyloid production and tau phosphorylation in Alzheimer disease

Kimura, R., Kamino, K., Yamamoto, M., Nuripa, A., Kida, T., Kazui, H., Hashimoto, R., Tanaka, T., Kudo, T., Yamagata, H., et al. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddl437 · Cited by 281

Amino- and carboxyl-terminal heterogeneity of β-amyloid peptides deposited in human brain

Saido, T. C., Yamao-Harigaya, W., Iwatsubo, T., & Kawashima, S. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)12970-0 · Cited by 270

β‐Amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases?

Carson, J. A., & Turner, A. J. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00855.x · Cited by 264

Atypical aging in down syndrome

Zigman, W. B. (2013) · Developmental Disabilities Research Reviews · doi:10.1002/ddrr.1128 · Cited by 262

Intraneuronal Aβ42 accumulation in Down syndrome brain: Original Articles

Mori, C., Spooner, E. T., Wisniewski, K. E., Wisniewski, T. M., Yamaguchi, H., Saido, T. C., Tolan, D. R., Selkoe, D. J., & Lemere, C. A. (2002) · Amyloid · doi:10.3109/13506120208995241 · Cited by 255

Full-length amyloid-beta (1-42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques.

Iwatsubo, T., Saido, T. C., Mann, D. M. A., Lee, V. M.-Y., & Trojanowski, J. Q. (1996) · Europe PMC (PubMed Central) · Cited by 248

Intraneuronal Aβ-Amyloid Precedes Development of Amyloid Plaques in Down Syndrome

Gyure, K. A., Durham, R., Stewart, W. F., Smialek, J. E., & Troncoso, J. C. (2001) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2001-125-0489-iaapdo · Cited by 248

Age-Related Distribution of Neuropathologic Changes in the Cerebral Cortex of Patients With Down's Syndrome

Hof, P. R. (1995) · Archives of Neurology · doi:10.1001/archneur.1995.00540280065020 · Cited by 242

Intracellular accumulation and resistance to degradation of the Alzheimer amyloid A4/beta protein.

Knauer, M. F., Soreghan, B., Burdick, D., Kosmoski, J., & Glabe, C. G. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.16.7437 · Cited by 233

Intracellular Mechanisms of Amyloid Accumulation and Pathogenesis in Alzheimer's Disease

Glabe, C. (2001) · Journal of Molecular Neuroscience · doi:10.1385/jmn:17:2:137 · Cited by 222

Early Amyloid Deposition in the Medial Temporal Lobe of Young Down Syndrome Patients: A Regional Quantitative Analysis

Leverenz, J. B., & Raskind, M. A. (1998) · Experimental Neurology · doi:10.1006/exnr.1997.6777 · Cited by 214

Abnormalities of the nucleus basalis in Down's syndrome

Casanova, M. F., Walker, L. C., Whitehouse, P. J., & Price, D. L. (1985) · Annals of Neurology · doi:10.1002/ana.410180306 · Cited by 202

The Tissue Plasminogen Activator-Plasminogen Proteolytic Cascade Accelerates Amyloid-β (Aβ) Degradation and Inhibits Aβ-Induced Neurodegeneration

Melchor, J. P., Pawlak, R., & Strickland, S. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-26-08867.2003 · Cited by 202

White Matter Hyperintensities and Cerebral Amyloidosis: Necessary and Sufficient for Clinical Expression of Alzheimer Disease?

Provenzano, F. A., Muraskin, J., Tosto, G., Narkhede, A., Wasserman, B. T., Griffith, E. Y., Guzman, V. A., Meier, I. B., Zimmerman, M. E., Brickman, A. M., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.1321 · Cited by 192

Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with down syndrome

Dowjat, W. K., Adayev, T., Kuchna, I., Nowicki, K., Palminiello, S., Hwang, Y. W., & Wegiel, J. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2006.11.026 · Cited by 190

Promoter Mutations That Increase Amyloid Precursor-Protein Expression Are Associated with Alzheimer Disease

Theuns, J., Brouwers, N., Engelborghs, S., Sleegers, K., Bogaerts, V., Corsmit, E., Pooter, T. D., van Duijn, C. M., Deyn, P. P. D., & Broeckhoven, C. V. (2006) · The American Journal of Human Genetics · doi:10.1086/504044 · Cited by 188

Temporal Accrual of Complement Proteins in Amyloid Plaques in Down's Syndrome with Alzheimer's Disease

Stoltzner, S. E., Grenfell, T. J., Mori, C., Wisniewski, K. E., Wisniewski, T. M., Selkoe, D. J., & Lemere, C. A. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64753-0 · Cited by 187

Adaptive Downregulation of Mitochondrial Function in Down Syndrome

Helguera, P. R., Seiglie, J., Rodríguez, J. A., Hanna, M., Helguera, G. F., & Busciglio, J. A. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2012.12.005 · Cited by 183

Down's syndrome: an atheroma-free model?

Murdoch, J. C., Rodger, J. C., Rao, S. S., Fletcher, C. D., & Dunnigan, M. G. (1977) · BMJ · doi:10.1136/bmj.2.6081.226 · Cited by 179

Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions

Schilling, S., Hoffmann, T., Manhart, S., Hoffmann, M., & Demuth, H. (2004) · FEBS Letters · doi:10.1016/s0014-5793(04)00300-x · Cited by 172

White matter integrity and vulnerability to Alzheimer’s disease: preliminary findings and future directions

Gold, B. T., Johnson, N. F., Powell, D. K., & Smith, C. D. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.07.009 · Cited by 170

Systemic Mitochondrial Dysfunction and the Etiology of Alzheimer's Disease and Down Syndrome Dementia

Coskun, P. E., Wyrembak, J., Derbereva, O., Melkonian, G., Doran, E. W., Lott, I. T., Head, E., Cotman, C. W., & Wallace, D. C. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100351 · Cited by 161

ASP1 (BACE2) Cleaves the Amyloid Precursor Protein at the β-Secretase Site

Hussain, I., Powell, D. J., Howlett, D. R., Chapman, G. A., Gilmour, L., Murdock, P. R., Tew, D. G., Meek, T. D., Chapman, C. G., Schneider, K., et al. (2000) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.2000.0884 · Cited by 156

Vascular burden and Alzheimer disease pathologic progression

Lo, R. Y., Jagust, W. J., Weiner, M., Aisen, P., Weiner, M., Aisen, P., Petersen, R., Jack, C. R., Jagust, W., Trojanowki, J. Q., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e31826c1b9d · Cited by 156

Precocious aging and dementia in patients with Down's syndrome.

Wisniewski, K. E., Howe, J., Williams, D. G., & Wisniewski, H. M. (1978) · PubMed · Cited by 153

Elevated plasma amyloid β-peptide 1–42 and onset of dementia in adults with Down syndrome

Schupf, N., Patel, B. N., Silverman, W. P., Zigman, W. B., Zhong, N., Tycko, B., Mehta, P. D., & Mayeux, R. P. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01657-3 · Cited by 148

Neuropathological Changes in Down's Syndrome Hippocampal Formation

Hyman, B. T. (1995) · Archives of Neurology · doi:10.1001/archneur.1995.00540280059019 · Cited by 147

Alpha- and beta-secretase activity as a function of age and beta-amyloid in Down syndrome and normal brain

Nistor, M., Don, M., Parekh, M., Sarsoza, F. M., Goodus, M. T., López, G., Kawas, C. H., Leverenz, J. B., Doran, E. W., Lott, I. T., et al. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.06.023 · Cited by 137

Pyroglutamate-3 Amyloid-β Deposition in the Brains of Humans, Non-Human Primates, Canines, and Alzheimer Disease–Like Transgenic Mouse Models

Frost, J. L., Le, K. X., Cynis, H., Ekpo, E., Kleinschmidt, M., Palmour, R. M., Ervin, F. R., Snigdha, S., Cotman, C. W., Saido, T. C., et al. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.05.005 · Cited by 135

The locus coeruleus and its possible role in ageing and degenerative disease of the human central nervous system

Mann, D. M. A. (1983) · Mechanisms of Ageing and Development · doi:10.1016/0047-6374(83)90100-8 · Cited by 135

The “Nonamyloidogenic” p3 Fragment (Amyloid β17-42) Is a Major Constituent of Down's Syndrome Cerebellar Preamyloid

Lalowski, M. M., Golabek, A. A., Lemere, C. A., Selkoe, D. J., Wı́sniewski, H. M., Beavis, R. C., Frangione, B., & Wısnıewskı, T. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.52.33623 · Cited by 134

Amyloid-β Toxicity and Tau Hyperphosphorylation are Linked Via RCAN1 in Alzheimer's Disease

Lloret, A., Badía, M.-C., Giraldo, E., Ermak, G., Alonso, M.-D., Pallardó, F. V., Davies, K. J. A., & Viña, J. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110890 · Cited by 133

Impairment of proteostasis network in Down syndrome prior to the development of Alzheimer's disease neuropathology: Redox proteomics analysis of human brain

Domenico, F. D., Coccia, R., Cocciolo, A., Murphy, M. P., Cenini, G., Head, E., Butterfield, D. A., Giorgi, A., Schininà, M. E., Mancuso, C., et al. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.04.013 · Cited by 132

Down syndrome and beta-amyloid deposition

Head, E., & Lott, I. T. (2004) · Current Opinion in Neurology · doi:10.1097/00019052-200404000-00003 · Cited by 129

Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome

Cenini, G., Dowling, A. L. S., Beckett, T. L., Barone, E., Mancuso, C., Murphy, M. P., LeVine, H., Lott, I. T., Schmitt, F. A., Butterfield, D. A., et al. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.10.001 · Cited by 126

Mortality of people with mental retardation in California with and without Down syndrome, 1986-1991.

Strauss, D., & Eyman, R. K. (1996) · PubMed · Cited by 121

Association between the interleukin-1β polymorphisms and Alzheimer's disease: A systematic review and meta-analysis

Bona, D. D., Plaia, A., Vasto, S., Cavallone, L., Lescai, F., Franceschi, C., Licastro, F., Colonna‐Romano, G., Lio, D., Candore, G., et al. (2008) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.07.003 · Cited by 119

Early Glycoxidation Damage in Brains from Down's Syndrome

Odetti, P. R., Angelini, G., Dapino, D., Zaccheo, D., Garibaldi, S., Dagna-Bricarelli, F., Piombo, G., Perry, G. L., Smith, M. A., Traverso, N., et al. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8186 · Cited by 118

Redox proteomics analysis to decipher the neurobiology of Alzheimer-like neurodegeneration: overlaps in Down's syndrome and Alzheimer's disease brain

Butterfield, D. A., Domenico, F. D., Swomley, A. M., Head, E., & Marzia Perluigi, A. (2014) · Biochemical Journal · doi:10.1042/bj20140772 · Cited by 112

Intracellular Accumulation of Insoluble, Newly Synthesized Aβn-42 in Amyloid Precursor Protein-transfected Cells That Have Been Treated with Aβ1–42

Yang, A. J., Chandswangbhuvana, D., Shu, T., Henschen, A., & Glabe, C. G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.29.20650 · Cited by 108

Increased plasma amyloid β protein 1–42 levels in Down syndrome

Mehta, P. D., Dalton, A. J., Mehta, S. P., Kim, K. S., Sersen, E. A., & Wisniewski, H. M. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00966-x · Cited by 108

Neuroinflammation in the Aging Down Syndrome Brain; Lessons from Alzheimer's Disease

Wilcock, D. M. (2012) · Current Gerontology and Geriatrics Research · doi:10.1155/2012/170276 · Cited by 104

Complement Association with Neurons and β-Amyloid Deposition in the Brains of Aged Individuals with Down Syndrome

Head, E., Azizeh, B. Y., Lott, I. T., Tenner, A. J., Cotman, C. W., & Cribbs, D. H. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0380 · Cited by 103

Link Between DYRK1A Overexpression and Several-Fold Enhancement of Neurofibrillary Degeneration With 3-Repeat Tau Protein in Down Syndrome

Węgiel, J., Kaczmarski, W., Barua, M., Kuchna, I., Nowicki, K., Wang, K.-C., Wegiel, J., Mazur‐Kolecka, B., Frackowiak, J., Mazur‐Kolecka, B., et al. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318202bfa1 · Cited by 98

Redox proteomics analysis of HNE-modified proteins in Down syndrome brain: clues for understanding the development of Alzheimer disease

Domenico, F. D., Pupo, G., Tramutola, A., Giorgi, A., Schininà, M. E., Coccia, R., Head, E., Butterfield, D. A., & Marzia Perluigi, A. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.03.027 · Cited by 98

RCAN1‐1L is overexpressed in neurons of Alzheimer's disease patients

Harris, C. D., Ermak, G., & Davies, K. J. A. (2007) · FEBS Journal · doi:10.1111/j.1742-4658.2007.05717.x · Cited by 97

Characterization of Aβ11-40/42 peptide deposition in Alzheimer’s disease and young Down’s syndrome brains: implication of N-terminally truncated Aβ species in the pathogenesis of Alzheimer’s disease

Liu, K., Solano, I., Mann, D. M. A., Lemere, C. A., Mercken, M. H., Trojanowski, J. Q., & Lee, V. M. ‐. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0077-5 · Cited by 96

Plasma Levels of amyloid β proteins Aβ1–40 and Aβ1–42(43) are elevated in Down's syndrome

Tokuda, T., Fukushima, T., Ikeda, S., Sekijima, Y., Shoji, S., Yanagisawa, N., & Tamaoka, A. (1997) · Annals of Neurology · doi:10.1002/ana.410410220 · Cited by 92

Protein expression of BACE1, BACE2 and APP in Down syndrome brains

Cheon, M. S., Dierssen, M., Kim, S. H., & Lübec, G. (2007) · Amino Acids · doi:10.1007/s00726-007-0618-9 · Cited by 92

Possible Compensatory Events in Adult Down Syndrome Brain Prior to the Development of Alzheimer Disease Neuropathology: Targets for Nonpharmacological Intervention

Head, E., Lott, I. T., Patterson, D. W., Doran, E. W., & Haier, R. J. (2007) · Journal of Alzheimer s Disease · doi:10.3233/jad-2007-11110 · Cited by 91

Plasma β amyloid and the risk of Alzheimer's disease in Down syndrome

Coppus, A. M. W., Schuur, M., Vergeer, J., Janssens, A. C. J. W., Oostra, B. A., Verbeek, M. M., & van Duijn, C. M. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.08.007 · Cited by 88

Is Brain Amyloid Production a Cause or a Result of Dementia of The Alzheimer's Type?

Struble, R. G., Ala, T., Patrylo, P. R., Brewer, G. J., & Yan, X. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100846 · Cited by 85

Down's syndrome and atherosclerosis

Ylä-Herttuala, S., Luoma, J., Nikkari, T., & Kivimäki, T. (1989) · Atherosclerosis · doi:10.1016/0021-9150(89)90110-x · Cited by 85

Change in plasma Aβ peptides and onset of dementia in adults with Down syndrome

Schupf, N., Zigman, W. B., Tang, M. X., Pang, D. I., Mayeux, R. P., Mehta, P. D., & Silverman, W. P. (2010) · Neurology · doi:10.1212/wnl.0b013e3181fb448b · Cited by 81

Plasma Amyloid-β as a Function of Age, Level of Intellectual Disability, and Presence of Dementia in Down Syndrome

Head, E., Doran, E. W., Nistor, M., HILL, M., Schmitt, F. A., Haier, R. J., & Lott, I. T. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-101335 · Cited by 75

Microglial pathology in Down syndrome

Xue, Q., & Streit, W. J. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0864-5 · Cited by 75

The Presence of Isoaspartic Acid in β-Amyloid Plaques Indicates Plaque Age

Fonseca, M. I., Head, E., Velázquez, P., Cotman, C. W., & Tenner, A. J. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7058 · Cited by 75

Oxidation of Aβ and Plaque Biogenesis in Alzheimer's Disease and Down Syndrome

Head, E., Garzon-Rodriguez, W., Johnson, J. K., Lott, I. T., Cotman, C. W., & Glabe, C. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0431 · Cited by 75

Cerebral microbleeds are related to loss of white matter structural integrity

Akoudad, S., de Groot, M., Koudstaal, P. J., van der Lugt, A., Niessen, W. J., Albert Hofman, D., Ikram, M. A., & Vernooij, M. W. (2013) · Neurology · doi:10.1212/01.wnl.0000436609.20587.65 · Cited by 74

Comparison of Intima-Media Thickness of the Carotid Artery and Cardiovascular Disease Risk Factors in Adults With Versus Without the Down Syndrome

Draheim, C. C., Geijer, J. R., & Dengel, D. R. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.06.079 · Cited by 71

Temporal cortex hypermetabolism in Down syndrome prior to the onset of dementia

Haier, R. J., Alkire, M. T., White, N. S., Uncapher, M. R., Head, E., Lott, I. T., & Cotman, C. W. (2003) · Neurology · doi:10.1212/01.wnl.0000098935.36984.25 · Cited by 71

The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease

Blennow, K., & Zetterberg, H. (2013) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.12.012 · Cited by 69

Role of Tau Protein in Neuronal Damage in Alzheimer's Disease and Down Syndrome

Cárdenas, A. M., Ardiles, Á. O., Barraza, N., Báez‐Matus, X., & Caviedes, P. A. (2012) · Archives of Medical Research · doi:10.1016/j.arcmed.2012.10.012 · Cited by 68

Low Blood Pressure in Down's Syndrome

Rd, M., McGrath, A., Davidson, G., Brown, J. J., Murray, G. D., & Lever, A. F. (1996) · Hypertension · doi:10.1161/01.hyp.28.4.569 · Cited by 68

BACE2 Expression Increases in Human Neurodegenerative Disease

Holler, C. J., Webb, R. L., Laux, A. L., Beckett, T. L., Niedowicz, D. M., Ahmed, R. R., Liu, Y., Simmons, C. R., Dowling, A. L. S., Spinelli, A., et al. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.09.034 · Cited by 66

Synaptophysin and Synaptojanin-1 in Down Syndrome are Differentially Affected by Alzheimer's Disease

Martin, S. B., Dowling, A. L. S., Lianekhammy, J., Lott, I. T., Doran, E., Murphy, M. P., Beckett, T. L., Schmitt, F. A., & Head, E. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-140795 · Cited by 64

Loss of neurones from cortical and subcortical areas in Down's syndrome patients at middle age

Mann, D. M. A., Yates, P. O., Marcyniuk, B., & Ravindra, C. (1987) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(87)90223-1 · Cited by 61

Lipids and lipoproteins in persons with Down's syndrome

Pueschel, S. M., Craig, W. Y., & Haddow, J. E. (1992) · Journal of Intellectual Disability Research · doi:10.1111/j.1365-2788.1992.tb00535.x · Cited by 60

Molecular Dating of Senile Plaques in the Brains of Individuals with Down Syndrome and in Aged Dogs

Azizeh, B. Y., Head, E., Ibrahim, M. A., Torp, R., Tenner, A. J., Kim, R. C., Lott, I. T., & Cotman, C. W. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7359 · Cited by 58

Diffuse Plaques in the Cerebellum and Corpus Striatum in Down's Syndrome Contain Amyloid β Protein (Aβ) only in the Form of Aβ42(43)

Mann, D. M. A., & Iwatsubo, T. (1996) · Neurodegeneration · doi:10.1006/neur.1996.0017 · Cited by 52

Exploring Alzheimer Molecular Pathology in Down's Syndrome Cerebrospinal Fluid

Portelius, E., Soininen, H. S., Andréasson, U., Zetterberg, H., Persson, R., Karlsson, G., Blennow, K., Herukka, S., & Mattsson, N. (2014) · Neurodegenerative Diseases · doi:10.1159/000358800 · Cited by 51

Plasma amyloid β protein 1–42 levels are increased in old Down Syndrome but not in young Down Syndrome

Mehta, P. D., Mehta, S. P., Fedor, B. L., Patrick, B. A., Emmerling, M. R., & Dalton, A. J. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(03)00275-1 · Cited by 50

Tau and apo E in CSF

Molina, L., Touchon, J., Herpé, M., Lefranc, D., Duplan, L., Cristol, J., Sabatier, R., Vermersch, P., Pau, B., & Mourton-Gilles, C. (1999) · Neuroreport · doi:10.1097/00001756-199911260-00005 · Cited by 49

BACE-2 is overexpressed in Down’s syndrome

Barbiero, L., Benussi, L., Ghidoni, R., Alberici, A., Russo, C., Schettini, G., Pagano, S., Parati, E. A., Mazzoli, F., Nicosia, F. M., et al. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00049-9 · Cited by 49

Stiffness of the large arteries in individuals with and without Down syndrome

Rodrigues, A., Coelho, Gonçalves, W. L. S., Gouvêa, Vasconcellos, Cunha, & Abreu (2011) · Vascular Health and Risk Management · doi:10.2147/vhrm.s21273 · Cited by 49

Characteristic developmental expression of amyloid β40, 42 and 43 in patients with Down syndrome

Hirayama, A., Horikoshi, Y., Maeda, M., Ito, M., & Takashima, S. (2003) · Brain and Development · doi:10.1016/s0387-7604(02)00209-7 · Cited by 45

DOES DOWN SYNDROME SUPPORT HOMOCYSTEINE THEORY OF ARTERIOSCLEROSIS?

Brattström, L. E., Englund, E. M., & Brun, A. E. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91772-7 · Cited by 45

Mitochondrial dysfunction and Down's syndrome: Is there a role for coenzyme Q10?

Tiano, L., & Busciglio, J. A. (2011) · BioFactors · doi:10.1002/biof.184 · Cited by 45

Elevated expression of beta-site amyloid precursor protein cleaving enzyme 2 in brains of patients with Down syndrome

Motonaga, K., Itoh, M., Becker, L. E., Goto, Y.-I., & Takashima, S. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00287-2 · Cited by 45

Altered Composition of Polyunsaturated Fatty Acyl Groups in Phosphoglycerides of Down's Syndrome Fetal Brain

Brooksbank, B. W. L., Martínez, M., & Balázs, R. (1985) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1985.tb12896.x · Cited by 41

Plasma β‐amyloid and duration of Alzheimer's disease in adults with Down syndrome

Prasher, V. P., Sajith, S. G., Mehta, P. D., Zigman, W. B., & Schupf, N. (2009) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2321 · Cited by 41

Intracerebral hemorrhage in two patients with Down's syndrome and cerebral amyloid angiopathy

Donahue, J. E., Khurana, J. S., & Adelman, L. S. (1998) · Acta Neuropathologica · doi:10.1007/s004010050789 · Cited by 40

CSF tau and Aβ42 levels in patients with Down’s syndrome

Tapiola, T., Soininen, H. S., & Pirttilä, T. (2001) · Neurology · doi:10.1212/wnl.56.7.979 · Cited by 39

Entorhinal cortex of aged subjects with Down's syndrome shows severe neuronal loss caused by neurofibrillary pathology

Sadowski, M. J., Wı́sniewski, H. M., Tarnawski, M. J., Kozlowski, P. B., Lach, B., & Węgiel, J. (1999) · Acta Neuropathologica · doi:10.1007/s004010050968 · Cited by 38

Increase in β-Amyloid Levels in Cerebrospinal Fluid of Children with Down Syndrome

Englund, H., Annerén, G., Gustafsson, J., Oxelgren, U. W., Wiltfang, J., Lannfelt, L., Blennow, K., & Höglund, K. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000109215 · Cited by 38

Parallel Compensatory and Pathological Events Associated with Tau Pathology in Middle Aged Individuals with Down Syndrome

Head, E., Lott, I. T., Hof, P. R., Bouras, C., Su, J., Kim, R., Haier, R. J., & Cotman, C. W. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.9.917 · Cited by 38

Cerebral amyloid angiopathy in Down's syndrome.

Belza, M. G., & Urich, H. (1986) · PubMed · Cited by 37

Amyloid β concentrations in older people with Down syndrome and dementia

Jones, E. L., Hanney, M., Francis, P. T., & Ballard, C. G. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.12.030 · Cited by 35

A quartet of Down's syndrome, Alzheimer's disease, cerebral amyloid angiopathy, and cerebral haemorrhage: interacting genetic risk factors

McCarron, M. O., Nicoll, J. A. R., & Graham, D. I. (1998) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.65.3.405 · Cited by 34

Plasma levels of amyloid ? 40 and 42 are independent from ApoE genotype and mental retardation in down syndrome

Cavani, S., Tamaoka, A., Moretti, A., Marinelli, L., Angelini, G., Stefano, S. D., Piombo, G., Cazzulo, V., Matsuno, S., Shoji, S., et al. (2000) · American Journal of Medical Genetics · doi:10.1002/1096-8628(20001127)95:3 · Cited by 33

Accumulation of Insoluble Amyloid-β in Down's Syndrome is Associated with Increased BACE-1 and Neprilysin Activities

Miners, J., Morris, S., Love, S., & Kehoe, P. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-101395 · Cited by 32

The Relationship of Plasma Aβ Levels to Dementia in Aging Individuals With Down Syndrome

Matsuoka, Y., Andrews, H., Becker, A. G., Gray, A. J., Mehta, P. D., Sano, M. C., Dalton, A. J., & Aisen, P. S. S. (2009) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e3181aba61e · Cited by 29

Prevalence and incidence of myocardial infarction and cerebrovascular accident in ageing persons with intellectual disability

Jansen, J., Rozeboom, W., Penning, C., & Evenhuis, H. M. (2012) · Journal of Intellectual Disability Research · doi:10.1111/j.1365-2788.2012.01567.x · Cited by 29

Altered Cerebrospinal Fluid Levels of Amyloid β and Amyloid Precursor-Like Protein 1 Peptides in Down’s Syndrome

Portelius, E., Hölttä, M., Soininen, H. S., Bjerke, M., Zetterberg, H., Westerlund, A., Herukka, S., Blennow, K., & Mattsson, N. (2014) · NeuroMolecular Medicine · doi:10.1007/s12017-014-8302-1 · Cited by 28

Ubiquitin-immunoreactive Dystrophic Neurites in Downʼs Syndrome Brains

Mattiace, L. A., Kress, Y., Davies, P., Ksiȩżak-Reding, H., Yen, S. H., & Dickson, D. W. (1991) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199109000-00003 · Cited by 28

β -Secretases, Alzheimer’s Disease, and Down Syndrome

Webb, R. L., & Murphy, M. P. (2012) · Current Gerontology and Geriatrics Research · doi:10.1155/2012/362839 · Cited by 26

β-Amyloid deposition and neurofibrillary tangle association with caspase activation in Down syndrome

Head, E., Lott, I. T., Cribbs, D. H., Cotman, C. W., & Rohn, T. T. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00705-x · Cited by 23

Cerebral amyloid angiopathy as a cause of an extensive brain hemorrhage in adult patient with Down's syndrome - a case report.

Mendel, T. A., Bertrand, E., Szpak, G. M., Stępień, T., & Wierzba‐Bobrowicz, T. (2010) · PubMed · Cited by 23

Variability of .BETA.-Amyloid Protein Deposited Lesions in Down's Syndrome Brains.

Ikeda, S.-I., Tokuda, T., Yanagisawa, N., Kametani, F., Ohshima, T., & Allsop, D. (1994) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.174.189 · Cited by 22

Cerebral amyloid angiopathy-related hemorrhage in a middle-aged patient with Down's syndrome

Naito, K., Sekijima, Y., & Ikeda, S. (2008) · Amyloid · doi:10.1080/13506120802524981 · Cited by 19

Plaques and Tangles: Searching for Primary Events in a Forest of Data

Cummings, B. J. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00049-3 · Cited by 16

Lectin-histochemical detection of degenerative glycoconjugate deposits in human brain

Nishimura, A., Sawada, S., Ushiyama, I., Yamamoto, Y., Nakagawa, T., Tanegashima, A., & Nishi, K. (2000) · Forensic Science International · doi:10.1016/s0379-0738(00)00228-0 · Cited by 15

Upregulation of phosphorylated αB-crystallin in the brain of children and young adults with Down syndrome

Palminiello, S., Jarząbek, K., Kaur, K., Walus, M., Rabe, A., Albertini, G., Golabek, A. A., & Kida, E. (2009) · Brain Research · doi:10.1016/j.brainres.2009.02.058 · Cited by 13

Secretory form of β-amyloid precursor protein is much abundantly contained in the cerebral white matter in human brain

Tokuda, T., Tanaka, K., Kametani, F., Ikeda, S., & Yanagisawa, N. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)91071-5 · Cited by 9

P4.57 STIFFNESS OF THE LARGE ARTERIES IN INDIVIDUALS WITH AND WITHOUT DOWN SYNDROME

Rodrigues, A. N., Coelho, L. O., Gonçalves, W. L. S., Vasconcellos, M., Cunha, R. S., Gouvêa, S. A., & Abreu, G. (2012) · Artery Research · doi:10.1016/j.artres.2012.09.204 · Cited by 9

Plasma amyloid β protein 1-42 levels in fetuses with Down syndrome

Bartha, J. L., & SOOTHILL, P. W. (2004) · Early Human Development · doi:10.1016/j.earlhumdev.2004.09.003 · Cited by 8

Untitled work

(1999) · doi:10.1002/1531-8249(199912)46:6

Untitled work

(2000) · doi:10.1002/1531-8249(200011)48:5

Diagnosis and Management of Dementia: Review

Arvanitakis, Z., Shah, R. C., & Bennett, D. A. (2019) · JAMA · doi:10.1001/jama.2019.4782 · Cited by 1,561

Bidirectional relationship between sleep and Alzheimer’s disease: role of amyloid, tau, and other factors

Wang, C., & Holtzman, D. M. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0478-5 · Cited by 615

Synaptopathies: synaptic dysfunction in neurological disorders – A review from students to students

Lepeta, K., Lourenco, M. V., Schweitzer, B. C., Martino Adami, P. V., Banerjee, P., Catuara‐Solarz, S., de La Fuente Revenga, M., Guillem, A. M., Haidar, M., Ijomone, O. M., et al. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13713 · Cited by 386

Telomere Biology and Human Phenotype

Turner, K. J., Vasu, V., & Griffin, D. K. (2019) · Cells · doi:10.3390/cells8010073 · Cited by 415

Dementia in Down syndrome: unique insights for Alzheimer disease research

Lott, I. T., & Head, E. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0132-6 · Cited by 383

Brain Aging and Alzheimer’s Disease in Down Syndrome

Helman, A. M., Pelt, K. L. V., Schmitt, F. A., & Head, E. (2022) · doi:10.1093/oxfordhb/9780190645441.013.22 · Cited by 1

Down syndrome and Alzheimer's disease: A link between development and aging

Lott, I. T., & Head, E. (2001) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/mrdd.1025 · Cited by 161

F3–01–02: Alzheimer's disease and Down syndrome

Lemere, C. A. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.04.223

Dementia in Down syndrome: unique insights for Alzheimer disease research

Lott, I. T., & Head, E. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0132-6 · Cited by 383

Down syndrome: a model for the study of Alzheimer’s disease and aging

Delabar, J. M., Blouin, J., Rahmani, Z., Créau, N., Chettouh, Z., Nicole, A., Bruel, A., de Blois, M., & Sinet, P. (1990) · New vistas in drug research · doi:10.1007/978-3-7091-9098-2_17 · Cited by 4